WhichPeps

Modified GRF(1-29) / 'CJC without DAC'

Short-acting GHRH analogue / marketplace nomenclature

Also known as: CJC without DAC· common market nameMod GRF 1-29· common name
Growth-hormone axis res…
Generic peptide vial illustrationModified GRF(1-29) / 'CJC without DAC'
Evidence levelHuman evidence
Human evidenceNone established
Regulatory statusNo specific FDA approval identified

What you need to know in 20 seconds

What is it?Short-acting GHRH analogue / marketplace nomenclature
Research focusGrowth-hormone axis research
Human evidenceNo dedicated peer-reviewed human clinical trial of the exact tetrasubstituted Modified GRF(1-29) / 'CJC-1295 without DAC' product was identified in this search. Related human studies of native GHRH(1-29), D-Ala2 analogues and CJC-1295 with DAC establish GHRH biology but are different molecules.
Regulatory statusNo specific FDA-approved product named 'CJC-1295 without DAC' was identified.
Main limitationsDirect human PK, dose-response, efficacy, long-term safety, body-composition benefit or equivalence of marketplace products.
SafetyEndocrine adverse effects and product-identity uncertainty; long-term non-indicated use is not established.
i
No dedicated peer-reviewed human clinical trial of the exact tetrasubstituted Modified GRF(1-29) / 'CJC-1295 without DAC' product was identified in this search. Related human studies of native GHRH(1-29), D-Ala2 analogues and CJC-1295 with DAC establish GHRH biology but are different molecules.

What the evidence actually supports

  • ✓This should be one of the site's clearest molecule-identity/evidence-provenance warnings.
  • ✓Use as mechanistic context, never as direct Mod GRF efficacy evidence.

What is not established / key limitations

  • ×No direct human trial identified for the exact tetrasubstituted peptide.
  • ×These studies did not test the four-substitution Mod GRF product.

Selected study & evidence records

D-Ala2 GHRH(1-29) pharmacokinetics in normal men

1994 · Human pharmacokinetic comparative study · n=10

D-Ala2 substitution reduced metabolic clearance and increased disappearance half-time from 4.3 to 6.7 minutes.

Study detail → Primary source ↗

GHRH(1-29) and D-Ala2 analogue GH-response study

1985 · Human dose-response pharmacology · n=5

Both peptides stimulated GH; the D-Ala2 analogue was approximately twice as potent as native GHRH(1-29) in this small study.

Study detail → Primary source ↗

Safety and unknowns

Endocrine adverse effects and product-identity uncertainty; long-term non-indicated use is not established.

Compound-specific human safety is not established. Related GHRH analogues can cause transient flushing and raise GH/IGF-I, but those data cannot define Mod GRF risk.

Technical details

Mechanism / biologyShort-acting GHRH-receptor agonism stimulates endogenous GH release; marketplace naming is inconsistent.
Route / formulation boundaryChemical identity should be confirmed because 'without DAC' is often used loosely for modified GRF(1-29).
Identity / data-quality noteDo not merge Modified GRF(1-29) with CJC-1295-DAC or native sermorelin. The literature belongs to distinct molecules.
Dosing evidence statusDosing research conclusion recorded. Human dosing exists for native GHRH(1-29)/sermorelin, but it should not be transferred to an unverified Modified GRF(1-29)/'CJC without DAC' product identity.
Identifiers & alternate namesCJC without DAC · CJC no DAC · Mod GRF 1-29 · CJC w/out DAC

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.